Questions and Answers
What is Desmopressin?
Desmopressin (D AVP, Stimate) is an antidiuretic hormone replacement and a vasopressin analog.
What are the actions and uses of Desmopressin?
It is a synthetic analog of human ADH that controls acute symptoms of diabetes insipidus.
What is the preferred route of administration for Desmopressin?
By mouth (oral administration) is preferred.
What is the duration of action for Desmopressin?
Signup and view all the answers
How is Desmopressin administered IV for diabetes insipidus?
Signup and view all the answers
What is the restriction following a Desmopressin IV injection?
Signup and view all the answers
What drug can increase the antidiuretic action of Desmopressin?
Signup and view all the answers
Which drugs can decrease the antidiuretic action of Desmopressin?
Signup and view all the answers
What are some adverse effects of Desmopressin that can be fatal?
Signup and view all the answers
What are other adverse effects of Desmopressin?
Signup and view all the answers
What are some intranasal adverse effects of Desmopressin?
Signup and view all the answers
What is considered an overdose of Desmopressin?
Signup and view all the answers
What are the three most common causes of diabetes insipidus?
Signup and view all the answers
What develops as a result of low antidiuretic hormone?
Signup and view all the answers
What is one common symptom of diabetes insipidus?
Signup and view all the answers
What must a nurse watch for once diabetes insipidus has been corrected?
Signup and view all the answers
Study Notes
Desmopressin Overview
- Desmopressin (D AVP, Stimate) is an antidiuretic hormone replacement and a vasopressin analog.
- It is a synthetic analog of human antidiuretic hormone (ADH) used to control acute symptoms of diabetes insipidus (DI).
Route of Administration
- Desmopressin is primarily administered orally, but can also be given intravenously (IV) and via parental routes.
Duration of Action
- The duration of action for Desmopressin is approximately 20 hours.
IV Administration Guidelines
- When administered IV for DI, desmopressin should be given undiluted over a period of 1 minute.
- Dosage must be verified by two nurses to ensure safety.
Post-Administration Monitoring
- Following an IV injection of Desmopressin, fluids should be restricted and monitored to prevent complications.
Drug Interactions
- Nonsteroidal anti-inflammatory drugs (NSAIDs) can enhance the antidiuretic action of Desmopressin.
- Drugs that may reduce the antidiuretic effect include heparin, alcohol, lithium, and epinephrine.
Adverse Effects
- Potentially fatal adverse effects include water intoxication, which can lead to drowsiness, headache, listlessness, convulsions, and coma.
- Other adverse effects may be transient headache, nausea, mild abdominal pain, flushing, hypertension, and pain or swelling at the injection site.
- Intranasal administration may cause congestion, rhinitis, and epistaxis (nosebleeds).
Overdose
- Severe water intoxication is the primary concern in instances of Desmopressin overdose.
Causes of Diabetes Insipidus
- Common causes of diabetes insipidus include brain tumors damaging the hypothalamus or pituitary gland, severe head injuries affecting these areas, and complications arising during brain or pituitary surgery.
Understanding Diabetes Insipidus
- Diabetes insipidus occurs due to low levels of antidiuretic hormone, leading to massive urination (polyuria) and dehydration.
- Hypotension may be a common symptom experienced by individuals with diabetes insipidus.
Post-Correction Monitoring
- After correcting diabetes insipidus, it is important for nurses to monitor for potential hypertension.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Test your knowledge on Desmopressin, a vital antidiuretic hormone replacement medication. This flashcard quiz covers its therapeutic and pharmacologic classes, administration routes, and key actions and uses. Perfect for students in pharmacology or endocrinology fields.
